D. E. Shaw & Co. Inc. Has $2.37 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

D. E. Shaw & Co. Inc. increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 37.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 315,263 shares of the biotechnology company's stock after acquiring an additional 86,173 shares during the period. D. E. Shaw & Co. Inc. owned about 0.15% of BioCryst Pharmaceuticals worth $2,371,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $46,000. R Squared Ltd acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $48,000. KBC Group NV grew its stake in shares of BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after buying an additional 4,537 shares in the last quarter. Raymond James Financial Inc. bought a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $80,000. Finally, Syon Capital LLC acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $99,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on BCRX shares. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price target on the stock. Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. Finally, Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded up $0.20 during mid-day trading on Monday, hitting $10.59. The company had a trading volume of 3,608,168 shares, compared to its average volume of 3,026,377. BioCryst Pharmaceuticals, Inc. has a 12 month low of $5.92 and a 12 month high of $11.11. The firm has a market cap of $2.22 billion, a P/E ratio of -17.36 and a beta of 1.08. The business's 50-day simple moving average is $8.44 and its 200-day simple moving average is $8.07.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The company's revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.28 EPS. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.